Q-omics provides the consensus-scored HIF1AN profile across patient tissues and cancer cell-line models. HIF1AN expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HIF1AN is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, HIF1AN RNA expression shows 21,136 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where HIF1AN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIF1AN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIF1AN survival associations across molecular data types. HIF1AN RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIF1AN RNA expression–survival associations across cancer types. High HIF1AN expression shows unfavorable associations in ACC, LIHC and OV, but favorable associations in UCS, KIRC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HIF1AN RNA expression.
This table summarizes HIF1AN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HIF1AN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIF1AN shows lower tumor expression in THCA, KICH and BLCA and higher tumor expression in LIHC, CHOL and LUSC. The LIHC box plot shows higher HIF1AN RNA expression in tumor versus normal tissue (log2 FC = +1.425, t-test p < 0.001).
This table shows molecular features associated with HIF1AN in patient tissues and cancer cell lines. In patient samples, HIF1AN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HIF1AN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
